Variants detected in this tumor have also been reported in other cancers:PDGFRA mutations in cervical adeno-squamous carcinomas;ERBB4 mutations in lung adenocarcinomas;FGFR3 mutations in breast, endometrial and ovarian cancers;CSF1R mutations in prostate cancer;EGFR mutations in lung adenocarcinomas;RET mutations in thyroid carcinomas;HRAS mutations in melanomas; andSMAD4 mutations in breast cancer. This evidence concerns the gene HRAS and breast carcinoma.